9 Meters Biopharma (NMTR) Competitors

Eiger BioPharmaceuticals (NASDAQ:EIGR) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.

Which has preferable valuation and earnings, EIGR or NMTR?

9 Meters Biopharma has lower revenue, but higher earnings than Eiger BioPharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eiger BioPharmaceuticals	$15.77M	0.00	-$96.78M	-$59.16	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

Does the media refer more to EIGR or NMTR?

In the previous week, Eiger BioPharmaceuticals had 1 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 1 mentions for Eiger BioPharmaceuticals and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 equaled Eiger BioPharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Eiger BioPharmaceuticals	Neutral
9 Meters Biopharma	Neutral

Does the MarketBeat Community prefer EIGR or NMTR?

Eiger BioPharmaceuticals received 377 more outperform votes than 9 Meters Biopharma when rated by MarketBeat users. However, 71.15% of users gave 9 Meters Biopharma an outperform vote while only 67.87% of users gave Eiger BioPharmaceuticals an outperform vote.

Company	Underperform	Outperform
Eiger BioPharmaceuticals	Outperform Votes 414 67.87%	Underperform Votes 196 32.13%
9 Meters Biopharma	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%

Which has more risk & volatility, EIGR or NMTR?

Eiger BioPharmaceuticals has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Do analysts prefer EIGR or NMTR?

Eiger BioPharmaceuticals currently has a consensus price target of $120.00, indicating a potential upside of ∞. 9 Meters Biopharma has a consensus price target of $1.70, indicating a potential upside of ∞.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eiger BioPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
9 Meters Biopharma	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do institutionals & insiders believe in EIGR or NMTR?

62.5% of Eiger BioPharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 4.2% of Eiger BioPharmaceuticals shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is EIGR or NMTR more profitable?

9 Meters Biopharma has a net margin of 0.00% compared to 9 Meters Biopharma's net margin of -590.80%. 9 Meters Biopharma's return on equity of -332.49% beat Eiger BioPharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eiger BioPharmaceuticals	-590.80%	-332.49%	-99.77%
9 Meters Biopharma	N/A	-584.97%	-159.45%

Summary

Eiger BioPharmaceuticals beats 9 Meters Biopharma on 10 of the 15 factors compared between the two stocks.